Platelet-inhibiting drugs for treatment of patients with acute coronary syndromes

Armen Hareyan's picture
Advertisement

Clinicians should carefully weigh the risks and benefits of when to administer platelet glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibitors for patients with acute coronary syndromes undergoing invasive treatment, according to a study in the February 14 issue of JAMA.

"In patients with acute coronary syndromes (ACS; unstable angina or non

Advertisement